Brian Flanagan Email & Phone Number

Osseo, Mn, Us

Greater Minneapolis-St. Paul Area

Publications1. Beckwith, J., J.A. Nyman, B. Flanagan, R. Schrover, and H-J Schuurman. 2012. A health-economic analysis of clinical islet transplantation. Clinical Transplantation. 26(1) 23-33.2. Beckwith, J., J.A. Nyman, B. Flanagan, R. Schrover, and H-J Schuurman. 2010. A health-economic analysis of porcine islet xenotransplantation. Xenotransplantation. 17: 233-242.3. Emanuele Cozzi, Mariachiara Tallacchini, E. Brian Flanagan, Richard N. Pierson III, Megan Sykes, and Harold Y. Vanderpool. 2009. The International Xenotransplantation Association Consensus Statement on Conditions for Undertaking Clinical Trials of Porcine Islet Products in Type 1 Diabetes. Chapter 1: Key ethical requirements and progress toward the definition of an international regulatory framework. 16: 203-214.

New York

Program Director – Islet Biology & Transplantation Specific accomplishments include:• Increased the Islet Biology & Transplantation portfolio to contain over 300 research grants, 6 direct reports, and an annual budget of over $45 million. • Conceived and established a $1.5M strategic partnership with the Roche Organ Transplant Research Foundation.• Established and directed the European Consortium for Islet Transplantation.• Negotiated the inclusion of 5 international sites into the Collaborative Islet Transplant Registry• Established an integrated network to distribute tissue to the research community.• Member of the Management Board for the JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium• Member of the NIH-NCRR Islet Cell Resource Program Steering Committee• Member of the OPTN/UNOS Pancreas Transplantation Committee - Financial Issues Subcommittee

Birmingham, Alabama Area

• Generated attenuated viral strains and identified unique properties with the potential to act as live viral vaccines.• Designed and performed independent research to elucidate the mechanism of protection and disease of Vesicular Stomatitis Virus (VSV).Publications (selected)1. Flanagan, E.B., et al. 2003. Vesicular stomatitis viruses with rearranged genomes have altered invasiveness and neuropathogenesis in mice. Journal of Virology. 77: 5740-5748.2. Flanagan, E. B., et al. 2001. Basis for the attenuation of novel VSVs having rearranged genomes. Gene Therapy. 8: S7.3. Flanagan, E. B., et al. 2001. Rearrangement of the genes of VSV eliminates clinical disease in the natural host: A new strategy for vaccine development. Journal of Virology. 75: 6107-6114.4. Flanagan, E. B., et al. 2000. Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response. Journal of Virology. 74: 7895-7902.5. Ball L.A., et al. 1999. Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. Journal of Virology. 73: 4705-4712.Presentations (selected)1. E. B. Flanagan, et al. Basis for the attenuation of novel VSVs having rearranged genomes. 2001. Replicating vectors for gene therapy. Harold W. Siebens Conference, Mayo Foundation, Rochester, Minnesota.2. B. Flanagan, et al. Rearrangement of the gene order of VSV results in the generation of viruses that can induce protective immunity in a natural host, swine, without causing damage. 2000. American Society for Virology, 19th annual meeting, Colorado State University, Fort Collins, Colorado.3. B. Flanagan, et al. Rearrangement of the gene order of VSV results in the generation of novel viruses capable of eliciting protection in mice and domestic swine. 1999. Molecular approaches to vaccine design. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.